Drug Trial Radar · NCT02290951
Study to Investigate the Safety and Tolerability of Odronextamab in Patients With CD20+ B-Cell Malignancies
Last checked: Nov 19, 2026Latest source record: Oct 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
200
Actual
Start
Jan 9, 2015
Primary completion
Aug 21, 2025
Study completion Aug 21, 2025
Sponsor
- Lead sponsor
- Regeneron PharmaceuticalsRegeneron (REGN)
- Sponsor type
- Industry
- First posted
- Nov 14, 2014
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study has two parts with distinct study objectives and study design. In part A, odronextamab is studied as an intravenous (IV) administration with a dose escalation and a dose expansion phase for B-NHL and CLL. The dose escalation phase for B-NHL and the CLL study are closed at the time of protocol amendment 17. In part B, odronextamab is studied as a subcutaneous (SC) administration with a dose finding and a dose expansion phase for B-NHL.
Conditions
- Non-Hodgkin Lymphoma
- Chronic Lymphocytic Leukemia
Interventions
Odronextamab multiple dose levelsDrug
Administered by intravenous (IV) infusion
Odronextamab multiple dose levelsDrug
Administered by subcutaneous (SC) injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety/overall frequency of adverse events (AEs)Time frame: Up to 24 months
- Safety/dose limiting toxicities (DLTs)Time frame: Up to 28 days
- Antitumor activity as measured by the objective response rate (ORR)Time frame: Through study completion, an average of 24 months
Locations
22 sites in 5 countries. Site status is shown where the registry gives one.
University of California, Irvine
Orange, California
Stanford University
Stanford, California
H. Lee Moffitt Cancer Center
Tampa, Florida
Massachusetts General Hospital
Boston, Massachusetts
Beth Israel Deaconess Medical Center
Boston, Massachusetts
Dana Farber Cancer Institute (Massachusetts General Hospital and Beth Israel)
Boston, Massachusetts
Mayo Clinic
Rochester, Minnesota
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey
Memorial Sloan Kettering Cancer Center
New York, New York
Weill Cornell Medical College
New York, New York
CHU Hôpital Lyon Sud
Lyon, France
Centre Henri Becquerel
Rouen, Haute-Normandie, France
Institut Gustave Roussy
Villejuif, Île-de-France Region, France
Universitatsklinikum Wurzburg
Würzburg, Bavaria, Germany
Rambam Health Care Campus - Hematology and Bone Marrow Transplantation Institute
Haifa, Israel
Lady Davis Carmel Medical Center
Haifa, Israel
Meir Medical Center
Kfar Saba, Central District, Israel
The Chaim Sheba Medical Center
Tel-Hashomer, Central District, Israel
Hadassah Medical Center
Jerusalem, Jerusalem, Israel
Assuta Ashdod University Hospital
Ashdod, Southern District, Israel
The Christie NHS Foundation Trust
Manchester, United Kingdom
Royal Cornwall Hospitals NHS Trust
Truro, Cornwall, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.